Back to Search
Start Over
An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
- Source :
- Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
- Publication Year :
- 2019
- Publisher :
- Nature Portfolio, 2019.
-
Abstract
- The HER2 monoclonal antibody, Trastuzumab, is the current standard treatment for HER2+ cancers but resistance to therapy occurs. Here, the authors show that activation of the PKR/eIF2α-P pathway exhibits anti-tumor effects in HER2+ cancer and is required for the response to Trastuzumab.
- Subjects :
- Science
Subjects
Details
- Language :
- English
- ISSN :
- 20411723
- Volume :
- 10
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nature Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7ecf6c59b1264893ab9910b75de10e72
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41467-019-10138-8